1. Cortes-Franco J, Raghunadharao D, Parikh P, et al. Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in imatinib(Drug information on imatinib)-resistant chronic myeloid leukemia (CML) patients who harbor the Bcr-Abl T315I mutation: Results of an ongoing multicenter phase 2/3 study. Blood. 2009;114:644.
2. Jabbour A, Kantarjian H, Jones, D, et al. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood. 2008;112:53-55.
3. Kovacic P. Hydroxyurea (therapeutics and mechanism): metabolism, carbamoyl nitroso, nitroxyl, radicals, cell signaling and clinical applications. Med Hypotheses. 2011;76:24-31.
4. Randi ML, Ruzzon E, Tezza F, et al. Toxocity and side effects of hydroxyurea used for primary thrombucythemia. Platelets. 2005;16:181-184.
5. Latagliata R, Spadea A, Cedrone M, et al. Symptomatic mucocutaneous toxicity of hydroyurea in Philadelphia chromosome-negative myeloproliferative neoplasms: the Mister Hyde face of a safe drug. Cancer. 2012;118:404-409.
6. Antonioli E, Guglielmelli P, Pieri L, et al. Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN. Am J Hematol. 2012;87:552-554.
7. Ballas SK, McCarthy WF, Guo N, et al. Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia. J Natl Med Assoc. 2009;101:1046-1051.
8. Best PJ, Daoud MS, Pittelkow MR, et al. Hydroxyurea-induced leg ulceration in 14 patients. Ann Intern Med. 1998;128:29-32.
9. Olesen LH, Pedersen BB. Hydroxyurea-induced leg ulcers in patients with chronic myeloproliferative disorders, Ugeskr Laeger. 2001;163:6908-6911.
10. Kato N, Kimura K, Yasukawa K, et al. Hydroxyurea-related leg ulcers in a patient with chronic myelogenous leukemia: A case report and review of the literature. J Dermatol. 1999;26:56-62.